909392-67-2

Upstream product

• 5794-88-7 5-Bromo-2-aminobenzoic acid 
• 67863-05-2 2-amino-N-isopropylacetamide 
• 909392-66-1 2-[6-bromo-2-(3-methoxyphenyl)-4-oxo-4H-quinazolin-3-yl]-N-isopropylacetamide 
• 909392-65-0 N-isopropyl-2-[2-(3-methoxyphenyl)-4-oxo-6-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)-4H-quinazolin-3-yl]acetamide 
• 77771-02-9 3-bromo-4-fluorobenzaldehyde 

Relevant academic research and scientific papers

Synthesis and SAR studies of novel 2-(6-aminomethylaryl-2-aryl-4-oxo- quinazolin-3(4H)-yl)acetamide Vasopressin V1b receptor antagonists

Synthesis and structure-activity relationships (SAR) of a novel series of vasopressin V1b antagonists are described. 2-(6-Aminomethylaryl-2- aryl-4-oxo-quinazolin-3(4H)-yl)acetamide have been identified with low nanomolar affinity for the V1b receptor and good selectivity with respect to related receptors V1a, V2 and OT. Optimised compound 16 shows a good pharmacokinetic profile and activity in a mechanistic model of HPA dysfunction.

2- (4-0X0-4H-QUINAZ0LIN-3-YL) ACETAMIDES AND THEIR USE AS VASOPRESSIN V3 ANTAGONISTS

The present invention relates to 2-(4-oxo4H-quinazolin-3-yl)acetamicle derivatives of formula (I), and to their use as vasopressin V3 antagonists, particularly for the treatment of depression.